Paradigm Biocapital Advisors LP Moon Lake Immunotherapeutics Transaction History
Paradigm Biocapital Advisors LP
- $2.62 Billion
- Q4 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 1,772,211 shares of MLTX stock, worth $75.9 Million. This represents 3.59% of its overall portfolio holdings.
Number of Shares
1,772,211
Previous 931,480
90.26%
Holding current value
$75.9 Million
Previous $47 Million
100.52%
% of portfolio
3.59%
Previous 1.69%
Shares
3 transactions
Others Institutions Holding MLTX
# of Institutions
136Shares Held
58.1MCall Options Held
124KPut Options Held
96.9K-
Bvf Inc San Francisco, CA19.8MShares$846 Million39.28% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$364 Million35.64% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.34MShares$143 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$119 Million2.15% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.19MShares$93.7 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.58B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...